Literature DB >> 19170966

Molecular characterization of patients with X-linked Hyper-IgM syndrome: description of two novel CD40L mutations.

A Rangel-Santos1, V L Wakim, C M Jacob, A C Pastorino, J M Cunha, A C Collanieri, J E Niemela, A S Grumach, A J S Duarte, D Moraes-Vasconcelos, J B Oliveira.   

Abstract

Type 1, X-linked Hyper-IgM syndrome (HIGM1) is caused by mutations in the gene encoding the CD154 protein, also known as CD40 ligand (CD40LG). CD40L is expressed in activated T cells and interacts with CD40 receptor expressed on B lymphocytes and dendritic cells. Affected patients present cellular and humoral immune defects, with infections by intracellular, opportunistic and extracellular pathogens. In the present study we investigated the molecular defects underlying disease in four patients with HIGM1. We identified four distinct CD40L mutations, two of them which have not been previously described. P1 harboured the novel p.G227X mutation which abolished CD40L expression. P2 had a previously described frame shift deletion in exon 2 (p.I53fsX65) which also prevented protein expression. P3 demonstrated the previously known p.V126D change in exon 4, affecting the TNF homology (TNFH) domain. Finally, P4 evidenced the novel p.F229L mutation also located in the TNFH domain. In silico analysis of F229L predicted the change to be pathological, affecting the many hydrophobic interactions of this residue. Precise molecular diagnosis in HIGM syndrome allows reliable detection of carriers, making genetic counselling and prenatal diagnosis possible.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19170966     DOI: 10.1111/j.1365-3083.2008.02198.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  3 in total

Review 1.  Pitfalls of "hyper"-IgM syndrome: a new CD40 ligand mutation in the presence of low IgM levels. A case report and a critical review of the literature.

Authors:  A Heinold; B Hanebeck; V Daniel; J Heyder; T H Tran; B Döhler; J Greil; F-M Müller
Journal:  Infection       Date:  2010-10-28       Impact factor: 3.553

2.  Clinical application of whole-genome sequencing in patients with primary immunodeficiency.

Authors:  Talal Mousallem; Thomas J Urban; K Melodi McSweeney; Sarah E Kleinstein; Mingfu Zhu; Mehdi Adeli; Roberta E Parrott; Joseph L Roberts; Brian Krueger; Rebecca H Buckley; David B Goldstein
Journal:  J Allergy Clin Immunol       Date:  2015-05-14       Impact factor: 10.793

3.  Clinical features and genetic analysis of 20 Chinese patients with X-linked hyper-IgM syndrome.

Authors:  Lin-Lin Wang; Wei Zhou; Wei Zhao; Zhi-Qing Tian; Wei-Fan Wang; Xiao-Fang Wang; Tong-Xin Chen
Journal:  J Immunol Res       Date:  2014-08-20       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.